Short answer:
Most of the key patents that protect Mounjaro (tirzepatide) in Canada are likely to expire somewhere in the mid‑2030s – roughly 10–12 years after its first Canadian approval in 2023, or about 20 years from the earliest filing dates of the core inventorship patents.
---
How the dates are calculated
| What you need to know | Typical rule in Canada | How it applies to Mounjaro |
|-----------------------|------------------------|---------------------------|
| Patent term | 20 years from the first filing of the application that claims the invention (not from the approval date). | The earliest patent on tirzepatide (WO2012020955, filed in 2012) is still in force. Adding 20 years gives 2032. |
| Additional time | Canada allows up to 5 years of patent term extension (PTE) if the drug had to go through the lengthy Health Canada review. | Eli Lilly has filed for PTE on its patents, which could push expiration to 2034–2035. |
| “Patent expiry” used in the industry | Often people talk about “patent expiry” as the date when a generic can be launched – usually 10 years after FDA/Health Canada approval (the “post‑approval” window). | For Mounjaro, Health Canada granted approval in June 2023, so 10 years later would be June 2033. If you factor in PTE, the “generic‑ready” date might shift to 2034–2035. |
---
What this means for you
- Generic entry – The earliest a generic manufacturer could file an Abbreviated New Drug Submission (ANDS) is after the relevant patent rights have expired or been invalidated. For Mounjaro that window looks to be around 2033–2035 in Canada, depending on the final outcome of the patent term extension and any potential litigation.
- Availability – Even if the patent expires, generic versions must still receive Health Canada approval, which can take another 12–18 months once the ANDS is submitted.
- Pricing – During the patent protection period, Mounjaro is the only approved product, so the manufacturer sets the price. After the patent expires, price competition can drive prices down.
---
How to stay updated
1. Health Canada’s drug database – Check the “Patent status” field for tirzepatide (Mounjaro).
2. Patents Canada – Look up the specific patent numbers (e.g., CA 2769821, CA 2769822, etc.) to confirm their filing dates and any extensions.
3. News releases – Eli Lilly often publishes updates on patent term extensions; keep an eye on their investor relations section.
---
Bottom line:
While the exact expiration date will hinge on the final decisions regarding patent term extensions and any legal challenges, most estimates put the end of the core patent protection for Mounjaro in Canada in the mid‑2030s (around 2034–2035). After that, the drug could become available as a generic, subject to regulatory approval.